Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.

Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta A, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O'Dwyer PJ.

JAMA Oncol. 2019 May 23. doi: 10.1001/jamaoncol.2019.0684. [Epub ahead of print]

PMID:
31120501
2.

Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.

Soulen MC, van Houten D, Teitelbaum UR, Damjanov N, Cengel KA, Metz DC.

Pancreas. 2018 Sep;47(8):980-984. doi: 10.1097/MPA.0000000000001115.

PMID:
30028446
3.

Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis.

Katona BW, Roccaro GA, Soulen MC, Yang YX, Bennett BJ, Riff BP, Glynn RA, Wild D, Nicolas GP, Pryma DA, Teitelbaum UR, Metz DC.

Pancreas. 2017 Oct;46(9):1121-1126. doi: 10.1097/MPA.0000000000000919.

4.

The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).

McMillan MT, Lewis RS, Drebin JA, Teitelbaum UR, Lee MK, Roses RE, Fraker DL, Vollmer CM.

Cancer. 2016 Feb 15;122(4):521-33. doi: 10.1002/cncr.29803. Epub 2015 Nov 20.

5.

Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.

Riff BP, Yang YX, Soulen MC, Pryma DA, Bennett B, Wild D, Nicolas G, Teitelbaum UR, Metz DC.

Clin Nucl Med. 2015 Nov;40(11):845-50. doi: 10.1097/RLU.0000000000000935.

PMID:
26284763
6.

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.

Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O'Dwyer PJ, Sepulveda A, Sun W.

Ann Oncol. 2013 Dec;24(12):3061-5. doi: 10.1093/annonc/mdt416. Epub 2013 Oct 20.

PMID:
24146220
7.

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.

Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ.

Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.

8.

Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.

Sohal DP, Metz JM, Sun W, Giantonio BJ, Plastaras JP, Ginsberg G, Kochman ML, Teitelbaum UR, Harlacker K, Heitjan DF, Feldman MD, Drebin JA, O'Dwyer PJ.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1485-91. doi: 10.1007/s00280-013-2147-4. Epub 2013 Mar 27.

PMID:
23532207
9.

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH.

Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.

10.

Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.

Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, Shaked A, Reddy R, Olthoff K.

Cancer. 2011 Jul 15;117(14):3187-92. doi: 10.1002/cncr.25889. Epub 2011 Jan 24.

11.

Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.

Teitelbaum UR, Haller DG.

Nat Rev Clin Oncol. 2009 May;6(5):250-1. doi: 10.1038/nrclinonc.2009.46.

PMID:
19390547

Supplemental Content

Loading ...
Support Center